HRES309-118

In Committee

Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.

118th Congress Introduced Apr 19, 2023

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

The bill requires that it is the sense of the House of Representatives that— by enacting the Federal Food, Drug, and Cosmetic Act and subsequent amendments, Congress intended for and authorized the Food and Drug Administration. It relies on reporting requirements and product standards. The main policy areas are Healthcare Consumers and Healthcare.

Who Benefits and How

Public beneficiaries or protected communities affected by the clause could face reduced risk.

Who Bears the Burden and How

Federal, state, or local agencies responsible for implementing the clause would take on compliance duties and Patients and health care consumers affected by the bill would take on compliance duties.

Key Provisions

  • Requires that it is the sense of the House of Representatives that— by enacting the Federal Food, Drug, and Cosmetic Act and subsequent amendments, Congress intended for and authorized the Food and Drug Administration...

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

The bill requires that it is the sense of the House of Representatives that— by enacting the Federal Food, Drug, and Cosmetic Act and subsequent amendments, Congress intended for and authorized the Food and Drug Administration.

Key Policy Areas

Healthcare Consumers, Healthcare

Primary Purpose

The bill requires that it is the sense of the House of Representatives that— by enacting the Federal Food, Drug, and Cosmetic Act and subsequent amendments, Congress intended for and authorized the Food and Drug Administration.

Policy Domains

Healthcare Consumers Healthcare

Whole bill

Identified Gains
  • Public beneficiaries or protected communities affected by the clause
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: ih
Public beneficiaries or protected communities affected by the clause:
Identified Costs
  • Federal, state, or local agencies responsible for implementing the clause
  • Patients and health care consumers affected by the bill
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: ih
Patients and health care consumers affected by the bill:
Federal, state, or local agencies responsible for implementing the clause:

Legislative Progress

In Committee
Introduced Committee Passed
Apr 19, 2023

Ms. Manning (for herself, Ms. Caraveo, Ms. Meng, Ms. Norton, …

Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Consumers Healthcare

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology